Study analysis · Cardiorenal Medicine · 2012
A vitamin that helps your cholesterol might be making your muscles ignore insulin.
Taking high-dose niacin for 16 weeks worsens your body's ability to use sugar by 22%, but a rise in the hormone adiponectin might partly protect against this effect.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study is like watching a small group of 9 people before and after they take a medicine. It can show us that two things changed together—like the medicine making one thing go up and another thing go down—but it can't tell us if one caused the other. That's because there was no comparison group of people who didn't take the medicine, and other things could have caused the changes.
What’s the bottom line?
Niacin is a vitamin that can help improve cholesterol, but it might also make it harder for your body to use sugar properly, which could increase diabetes risk. This study looked at whether a hormone released by fat, called adiponectin, could help reduce that negative effect.
How strong is this study?
This study is pretty small, with only 9 people, and it didn't have a separate group to compare against. That makes it hard to trust the results a lot, because we don't know if the changes happened just by chance or because of something else. The good part is they used a very precise machine to measure insulin sensitivity, but the small size and lack of comparison mean the results are not very strong.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
14 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control groupno control group
- Sample size (n=9)+0.9/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 546 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is a before-after study with no control group, no randomization, and no blinding. Observational design cannot rule out confounding factors or establish cause-effect. The authors themselves state the association does not establish causation.
No Conflicts
No conflicts of interest identified
No conflicts of interest declared; all authors are from academic institutions.
The study uses Niaspan (Abbott) but no industry ties or funding are mentioned. The text does not include a conflict of interest or funding statement.
Key takeaways
- 01
After 16 weeks of taking niacin, the body's ability to move sugar into muscles dropped by 22%.
- 02
At the same time, a hormone called adiponectin increased by about 30% (though this wasn't quite statistically significant).
- 03
The people who had a bigger increase in adiponectin had a smaller drop in sugar handling.
- 04
The 22% reduction in insulin sensitivity is clinically meaningful and could increase long-term diabetes risk, but the link with adiponectin suggests the effect might be partially countered if adiponectin rises enough.
Surprising findings
- Niacin caused a 22% reduction in insulin-mediated glucose disposal despite increasing adiponectin, which usually improves insulin sensitivity.Conventional wisdom says boosting adiponectin should help, but niacin's insulin-desensitizing effect was stronger.
- Basal insulin nearly doubled (82% increase) after 16 weeks of niacin therapy.Such a large compensatory rise in insulin is rarely seen with short-term interventions and indicates significant systemic insulin resistance.
- The increase in adiponectin was not statistically significant (p=0.08) despite being similar to larger studies.With only 9 subjects, the study was underpowered to detect this change, yet the correlation with insulin sensitivity was significant – suggesting a real biological effect.
Practical takeaways
If you take niacin (Niaspan) for cholesterol, ask your doctor to check your fasting glucose and insulin every few months.
This study only included obese NAFLD patients; results may differ in leaner or healthier populations.
low confidenceConsider alternatives to niacin for HDL raising, like exercise or fish oil, if you have prediabetes or metabolic syndrome.
Niacin's effects on insulin may be temporary or dose-dependent; more research needed.
low confidenceDon't stop niacin without medical advice – the cardiovascular benefits may still outweigh risks for some patients.
The study is short-term (16 weeks); long-term effects are unknown.
low confidenceWhy this study matters
The Niacin Paradox
Niacin (Niaspan) raises HDL cholesterol but also reduces insulin sensitivity by 22% in obese people with fatty liver, independent of weight change. This contradicts the expectation that niacin's adiponectin-boosting effect would improve insulin action.
Many people take niacin for heart health, unaware it could increase diabetes risk. This study quantifies the trade-off.
Adiponectin: The Partial Protector
Niacin increased adiponectin by ~30% (p=0.08). Those with the biggest adiponectin rise had the smallest loss of insulin sensitivity (r=0.67, p=0.05). This suggests adiponectin may offset some, but not all, of niacin's harmful effects.
Shows that even a 'good' hormone can't fully counteract a drug's side effect, highlighting the complexity of metabolism.
Niacin and Fatty Liver: A Double-Edged Sword
This study specifically looked at obese NAFLD patients. Niacin didn't change body fat but nearly doubled fasting insulin (82% increase) and increased liver glucose production by ~20%. That's a sign of worsening liver insulin resistance.
People with fatty liver are already at high diabetes risk; niacin might accelerate that risk.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Niacin is a vitamin that can help improve cholesterol, but it might also make it harder for your body to use sugar properly, which could increase diabetes risk. This study looked at whether a hormone released by fat, called adiponectin, could help reduce that negative effect.
Research results
After 16 weeks of taking niacin, the body's ability to move sugar into muscles dropped by 22%. At the same time, a hormone called adiponectin increased by about 30% (though this wasn't quite statistically significant). The people who had a bigger increase in adiponectin had a smaller drop in sugar handling.
What this means - more context
The 22% reduction in insulin sensitivity is clinically meaningful and could increase long-term diabetes risk, but the link with adiponectin suggests the effect might be partially countered if adiponectin rises enough.
To evaluate whether Niaspan-induced changes in plasma adiponectin concentration are associated with a blunting of Niaspan's adverse effect on insulin action in obese subjects with NAFLD.
16 weeks of Niaspan therapy caused a 22% reduction in insulin-mediated glucose disposal, which was inversely correlated with an increase in plasma adiponectin (r=0.67, p=0.05). Adiponectin increased ~30% (p=0.08). Basal insulin nearly doubled and hepatic glucose production increased ~20%.
Methods Used
Hyperinsulinemic-euglycemic clamp before and after 16 weeks of Niaspan (titrated to 2,000 mg/day) in 9 obese adults with NAFLD (age 43±5, BMI 35.1±1.3).
Main Finding
Niaspan causes skeletal muscle insulin resistance independent of body weight or fat; the rise in adiponectin may partially offset this adverse effect.
Confidence Level
Low – small sample (n=9), no control group, open-label design, p=0.08 for adiponectin increase.
Study Flags
Red Flags
- •Very small sample size (n=9)
- •No control or placebo group
- •Open-label design; no blinding
Surprising Findings
Niacin caused a 22% reduction in insulin-mediated glucose disposal despite increasing adiponectin, which usually improves insulin sensitivity.
Conventional wisdom says boosting adiponectin should help, but niacin's insulin-desensitizing effect was stronger.
Practical Takeaways
If you take niacin (Niaspan) for cholesterol, ask your doctor to check your fasting glucose and insulin every few months.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 546 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study is like watching a small group of 9 people before and after they take a medicine. It can show us that two things changed together—like the medicine making one thing go up and another thing go down—but it can't tell us if one caused the other. That's because there was no comparison group of people who didn't take the medicine, and other things could have caused the changes.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Use of hyperinsulinemic-euglycemic clamp (gold standard for insulin sensitivity measurement)
- Stable isotope tracer methodology for glucose kinetics
- Prospective design with pre- and post-intervention measurements
Weaknesses
- No control group (before-after design)
- No randomization
- No blinding
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Niacin is a vitamin that can help improve cholesterol, but it might also make it harder for your body to use sugar properly, which could increase diabetes risk. This study looked at whether a hormone released by fat, called adiponectin, could help reduce that negative effect.
Research results
After 16 weeks of taking niacin, the body's ability to move sugar into muscles dropped by 22%. At the same time, a hormone called adiponectin increased by about 30% (though this wasn't quite statistically significant). The people who had a bigger increase in adiponectin had a smaller drop in sugar handling.
What this means - more context
The 22% reduction in insulin sensitivity is clinically meaningful and could increase long-term diabetes risk, but the link with adiponectin suggests the effect might be partially countered if adiponectin rises enough.
To evaluate whether Niaspan-induced changes in plasma adiponectin concentration are associated with a blunting of Niaspan's adverse effect on insulin action in obese subjects with NAFLD.
16 weeks of Niaspan therapy caused a 22% reduction in insulin-mediated glucose disposal, which was inversely correlated with an increase in plasma adiponectin (r=0.67, p=0.05). Adiponectin increased ~30% (p=0.08). Basal insulin nearly doubled and hepatic glucose production increased ~20%.
Methods Used
Hyperinsulinemic-euglycemic clamp before and after 16 weeks of Niaspan (titrated to 2,000 mg/day) in 9 obese adults with NAFLD (age 43±5, BMI 35.1±1.3).
Main Finding
Niaspan causes skeletal muscle insulin resistance independent of body weight or fat; the rise in adiponectin may partially offset this adverse effect.
Confidence Level
Low – small sample (n=9), no control group, open-label design, p=0.08 for adiponectin increase.
Study Flags
Red Flags
- •Very small sample size (n=9)
- •No control or placebo group
- •Open-label design; no blinding
Surprising Findings
Niacin caused a 22% reduction in insulin-mediated glucose disposal despite increasing adiponectin, which usually improves insulin sensitivity.
Conventional wisdom says boosting adiponectin should help, but niacin's insulin-desensitizing effect was stronger.
Practical Takeaways
If you take niacin (Niaspan) for cholesterol, ask your doctor to check your fasting glucose and insulin every few months.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 546 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study is like watching a small group of 9 people before and after they take a medicine. It can show us that two things changed together—like the medicine making one thing go up and another thing go down—but it can't tell us if one caused the other. That's because there was no comparison group of people who didn't take the medicine, and other things could have caused the changes.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Use of hyperinsulinemic-euglycemic clamp (gold standard for insulin sensitivity measurement)
- Stable isotope tracer methodology for glucose kinetics
- Prospective design with pre- and post-intervention measurements
Weaknesses
- No control group (before-after design)
- No randomization
- No blinding
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study is pretty small, with only 9 people, and it didn't have a separate group to compare against. That makes it hard to trust the results a lot, because we don't know if the changes happened just by chance or because of something else. The good part is they used a very precise machine to measure insulin sensitivity, but the small size and lack of comparison mean the results are not very strong.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
14 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control groupno control group
- Sample size (n=9)+0.9/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 546 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is a before-after study with no control group, no randomization, and no blinding. Observational design cannot rule out confounding factors or establish cause-effect. The authors themselves state the association does not establish causation.
No Conflicts
No conflicts of interest identified
No conflicts of interest declared; all authors are from academic institutions.
The study uses Niaspan (Abbott) but no industry ties or funding are mentioned. The text does not include a conflict of interest or funding statement.